Published in Lancet on October 24, 1998
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) 4.37
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med (2004) 2.67
The complexities of predictive genetic testing. BMJ (2001) 2.36
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A (2001) 2.09
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res (2006) 2.05
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed (2005) 1.58
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer (2001) 1.44
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res (2005) 1.31
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27
The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet (2002) 1.26
Interaction between genetic susceptibility and early-life environmental exposure determines tumor-suppressor-gene penetrance. Proc Natl Acad Sci U S A (2005) 1.19
BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res (2003) 1.17
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res (2003) 1.03
Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int (2013) 1.01
Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. Breast Cancer Res Treat (2007) 1.00
Hereditary breast cancer in Jews. Fam Cancer (2004) 0.99
Founder populations and their uses for breast cancer genetics. Breast Cancer Res (2000) 0.99
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2000) 0.98
The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res (2004) 0.98
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res (2008) 0.97
Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci (2004) 0.93
Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells. Mol Cancer (2010) 0.93
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet (2001) 0.92
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
Identification of racial disparities in breast cancer mortality: does scale matter? Int J Health Geogr (2010) 0.90
Challenging and complex decisions in the management of the BRCA mutation carrier. J Womens Health (Larchmt) (2013) 0.89
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J Cancer (2009) 0.89
Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoter. J Biol Chem (2008) 0.88
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer (2008) 0.87
BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer (2010) 0.86
CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer (2003) 0.85
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet (2012) 0.84
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer (2004) 0.83
Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. BMC Cancer (2007) 0.83
Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect". BMC Cancer (2016) 0.81
BRCA1 and BRCA2 testing: weighing the demand against the benefits. Am J Hum Genet (1999) 0.81
Why should primary care physicians know about breast cancer genetics? West J Med (2001) 0.79
Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. Cancer Med (2015) 0.78
Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. Fam Cancer (2011) 0.78
Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg (2000) 0.78
Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Fam Cancer (2001) 0.78
Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. Open Med (2007) 0.77
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget (2016) 0.77
Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India. J Cancer Res Clin Oncol (2007) 0.77
Hereditary breast and ovarian cancer. Hered Cancer Clin Pract (2008) 0.77
Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Mol Genet Genomic Med (2015) 0.76
Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Fam Cancer (2007) 0.76
The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2012) 0.75
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol (2015) 0.75
BRCA1 and BRCA2: penetrating the clinical arena. Lancet (1998) 0.75
Association of Cancer Incidence and Duration of Residence in Geothermal Heating Area in Iceland: An Extended Follow-Up. PLoS One (2016) 0.75
Genetics through a primary care lens. West J Med (2001) 0.75
Trial of prophylactic mastectomy is needed. BMJ (1999) 0.75
The clinical genetics of prostate cancer. Hered Cancer Clin Pract (2004) 0.75
Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. Fam Cancer (2015) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst (1993) 9.48
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol (1986) 6.88
Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. N Engl J Med (1997) 6.72
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials (2000) 5.37
Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol (1990) 4.63
HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA (2000) 4.62
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer (1995) 4.59
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst (2000) 3.81
Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica (1997) 3.67
Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. J Natl Cancer Inst (1997) 3.61
Validation studies using an alloyed gold standard. Am J Epidemiol (1993) 3.56
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst (1999) 2.98
Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol (2001) 2.97
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst (2001) 2.73
The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med (1984) 2.70
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
Random digit dialing in selecting a population-based control group. Am J Epidemiol (1984) 2.64
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer (1990) 2.61
Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J (2002) 2.60
Screening for cancer of the uterine cervix in Iceland 1965--1978. Acta Obstet Gynecol Scand (1982) 2.57
Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer (1977) 2.56
Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol (2001) 2.48
Attributable risk: advantages of a broad definition of exposure. Am J Epidemiol (1994) 2.45
Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ (1992) 2.39
Association between childhood acute lymphoblastic leukemia and use of electrical appliances during pregnancy and childhood. Epidemiology (1998) 2.33
The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet (1998) 2.32
Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet (1997) 2.28
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis (2000) 2.24
Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res (1990) 2.21
Non-differential misclassification and bias towards the null: a clarification. Occup Environ Med (1995) 2.15
Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med (1995) 2.14
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. Eur Heart J (1998) 1.99
Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst (1998) 1.91
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med (1998) 1.87
Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst (2001) 1.86
Decline in ischaemic heart disease in Iceland and change in risk factor levels. BMJ (1991) 1.86
Are children living near high-voltage power lines at increased risk of acute lymphoblastic leukemia? Am J Epidemiol (2000) 1.82
Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control (2001) 1.82
Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health (2001) 1.80
Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev (1997) 1.80
Incidence of cancer among commercial airline pilots. Occup Environ Med (2000) 1.79
Bladder cancer, drinking water source, and tap water consumption: a case-control study. J Natl Cancer Inst (1987) 1.77
A case-control study of cancer of the esophagus and gastric cardia in Linxian. Int J Cancer (1989) 1.75
A cohort study of smoking, alcohol consumption, and dietary factors for pancreatic cancer (United States). Cancer Causes Control (1993) 1.74
Urinary tract infection and risk of bladder cancer. Am J Epidemiol (1984) 1.70
Paternal cigarette smoking and the risk of childhood cancer among offspring of nonsmoking mothers. J Natl Cancer Inst (1997) 1.69
Low iron-binding capacity as a risk factor for myocardial infarction. Circulation (1994) 1.68
A cohort study of stomach cancer in a high-risk American population. Cancer (1991) 1.67
Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med (1985) 1.64
A cohort study of cancer among benzene-exposed workers in China: overall results. Am J Ind Med (1996) 1.63
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (1999) 1.61
The kin-cohort study for estimating penetrance. Am J Epidemiol (1998) 1.60
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
Trends in cancer incidence in the Nordic countries. A collaborative study of the five Nordic Cancer Registries. Acta Pathol Microbiol Immunol Scand Suppl (1986) 1.60
Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst (2000) 1.59
Breastfeeding and reduced risk of breast cancer in an Icelandic cohort study. Am J Epidemiol (2001) 1.59
Factors influencing the age at natural menopause. J Chronic Dis (1987) 1.57
Hyperendemic Streptococcus pyogenes infection despite prophylaxis with penicillin G benzathine. N Engl J Med (1991) 1.57
Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst (1989) 1.55
Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res (1997) 1.54
Cancer of the upper gastrointestinal tract among patients with pernicious anemia: a case-cohort study. Scand J Gastroenterol (2000) 1.53
The design and analysis of case-control studies with biased sampling. Biometrics (1990) 1.52
HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer (2001) 1.52
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Epidemiology of bladder cancer. Hematol Oncol Clin North Am (1992) 1.50
BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med (Berl) (1997) 1.49
A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics (2001) 1.49